| Name | N-{(2R)-3-(7-Methyl-1H-indazol-5-yl)-1-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-1-oxo-2-propanyl}-4-(2-oxo-1,2-dihydro-3-quinolinyl)-1-piperidinecarboxamide |
|---|---|
| Synonyms |
1-Piperidinecboxamide, 4-(1,2-dihydro-2-oxo-3-quinolinyl)-N-[(1R)-1-[(7-methyl-1H-indazol-5-yl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]
Vazegant (R)-N-(3-(7-Methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-cboxamide N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-1-oxopropan-2-yl]-4-(2-oxo-1H-quinolin-3-yl)piperidine-1-cboxamide Zavegant (Vazegant Zavegant (BHV-3500, BMS-742413) Zevagant Zavegant Vazegant free base N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-1-oxopropan-2-yl]-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-cboxamide BHV-3500 BMS 742413) |
| Description | Vazegepant is the first intranasal CGRP receptor antagonist for the study the acute research of migraine[1][2]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 933.7±65.0 °C at 760 mmHg |
| Molecular Formula | C36H46N8O3 |
| Molecular Weight | 638.80 |
| Flash Point | 518.5±34.3 °C |
| Exact Mass | 638.369263 |
| LogP | 4.30 |
| Vapour Pressure | 0.0±0.3 mmHg at 25°C |
| Index of Refraction | 1.648 |